8月17日，金斯瑞生物科技盘中上涨3.3%，报25.9港元/股，成交额1.29亿港元。
消息面上，公司于8月16日发布中期业绩，核心业务表现大幅超预期。报告期内集团收益约4.04亿美元，按基本基准同比增长27.3%；经调整净利润约6250万美元，同比增长203.3%；经调整经营利润约9400万美元，同比增长102.8%。AIDD相关业务同比实现翻倍增长，连续三个半年度保持快速增长趋势。受传奇生物权益法入账影响，集团期内仍录得净亏损1.29亿美元，但较上年同期收窄29.25%。收益增长主要受AI驱动药物发现需求持续上涨、CRDMO行业上游需求强劲复苏及工业酶业务持续扩张推动。
金斯瑞生物科技是一家全球领先的生命科学研发与制造服务提供商，业务覆盖基因合成、蛋白生产、抗体开发、生物制剂CDMO及细胞疗法等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.